Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) who failed first-line standard therapy of immunotheray and antiangiogenic therapy.
Hepatocellular Carcinoma
DRUG: Cadonilimab+Lenvatinib
Objective Response Rate (ORR) per RECIST v1.1, Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to RECIST v1.1., Up to two years
Objective Response Rate (ORR) per mRECIST, Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to mRECIST., Up to two years|Disease control Rate (DCR), Defined as the proportion of patients who achieved complete response (CR), partial response (PR), and stable disease (SD) according to RECIST v1.1 and mRECIST respectively., Up to two years|Duration of response (DoR), Defined as the time from the first dose to disease progression or death in patients who achieve complete or partial response., Up to two years|Progression-Free-Survival (PFS), Defined as the time between signing the informed consent form to the disease progression (according to RECIST v1.1 criteria) or death due to any cause., Up to two years|Overall survival Overall survival (OS), Defined as the time between the first dose to death due to any causes., Up to three years|Incidence of Adverse Events, Adverse events (AEs) ; serious adverse events (SAEs); Treatment related Adverse events (TRAEs); Use NCI-CTCAE version 5.0 for classification and grading., Up to two years
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) who failed first-line standard therapy of immunotheray and antiangiogenic therapy.